David A. Siegel Achilles Therapeutics PLC Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 22,400 shares of ACHL stock, worth $25,311. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,400
Previous 23,500
4.68%
Holding current value
$25,311
Previous $19,000
15.79%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ACHL
# of Institutions
24Shares Held
24.3MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$12.5 Million14.01% of portfolio
-
Bml Capital Management, LLC Zionsville, IN4.1MShares$4.63 Million2.46% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.7 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.82 Million0.11% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.69 Million0.12% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $46.1M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...